Cabergoline

• CAT Number: I004957
• CAS Number: 81409-90-7
• Molecular Formula: C26H37N5O2
• Molecular Weight: 451.60
• Purity: ≥95%
• Synonyms: (6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide
• Target: Neuronal Signaling
• Solubility: DMSO: ≥ 33 mg/mL
• Storage: Store at -20℃
• IUPAC Name: (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
• InChI: InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
• InChIKey: KORNTPPJEAJQIU-KJXAQDMKSA-N
• SMILES: CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C

Cabergoline (Cat No.: I004957) is a potent dopamine receptor agonist primarily targeting D2 receptors. It is widely used to treat hyperprolactinemia by inhibiting prolactin secretion from the pituitary gland. Additionally, cabergoline has applications in managing Parkinson’s disease and other dopaminergic disorders due to its long-lasting effects and high receptor affinity. Its utility in reducing prolactin-related symptoms and its potential neuroprotective properties make it an essential compound in endocrinology and neurology research, contributing to advancements in therapeutic strategies for dopamine-related conditions.